High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

A retrospective study of hepatosplenic candidiasis in patients with acute leukemia from a single centre was performed. The significance of age, sex, type of leukemia, dose of cytosine arabinoside (Ara-C), duration of neutropenia, steroid use and period of therapeutic antibiotics in the development of hepatosplenic candidiasis was analyzed, using logistic regression analysis. Nine of 51 patients had hepatosplenic candidiasis. Ara-C use was highly associated with the development of hepatosplenic candidiasis (p = 0.001); with a high association with a higher dose (p <0.0001). On the basis of these results consideration should be given to further trial of antifungal prophylaxis for patients receiving high dose Ara-C.

Original languageEnglish
Pages (from-to)469-474
Number of pages6
JournalLeukemia and Lymphoma
Volume27
Issue number5-6
Publication statusPublished - 1997

Keywords

  • Hepatosplenic candidiasis
  • HiDAC major risk factor
  • High dose cytosine arabinoside
  • Leukemia
  • Risk factors in leukemia

Cite this